Evive Completed F-627 Phase I Dosing in Australia

2010-11-22. Evive Biotech completed F-627 Phase I dosing in Australia. The primary objective of the study is to investigate the safety profile of F-627 in healthy volunteers. The secondary objective of the study is to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) properties of F-627. F-627 is a recombinant G-CSF dimer, expressed in mammalian cells.

The release as fetched from its publisher. evivebiotech.com ↗